ArticleLeukemia2020
Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome.
Abstract readLetter
In one paragraph
Article in Leukemia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- [Chinese expert consensus on the diagnosis and treatment of large granular lymphocytic leukemia (2026)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- T lymphocytes and natural killer cells in myelodysplastic syndromes: function, dysfunction, and therapeutic potential.Frontiers in immunology · 2026Review
- Clinical features and influencing factors analysis of T-cell large granular lymphocytic leukemia complicated with pure red cell aplasia.Frontiers in immunology · 2025Article
- The constitutive activation of STAT3 gene and its mutations are at the crossroad between LGL leukemia and autoimmune disorders.Blood cancer journal · 2024Review
- The immunobiology of myelodysplastic neoplasms: a mini-review.Frontiers in immunology · 2024Review
- Distinct mutational pattern of T-cell large granular lymphocyte leukemia combined with pure red cell aplasia: low mutational burden of STAT3.Scientific reports · 2023Article
- Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia.Cold Spring Harbor molecular case studies · 2023Article
- Distinguishing STAT3/STAT5B-mutated large granular lymphocyte leukemia from myeloid neoplasms by genetic profiling.Blood advances · 2023Article
- Association ofAnnals of translational medicine · 2022Article
- All that glitters is not LGL Leukemia.Leukemia · 2022Review
- Article
- Clonality in immune aplastic anemia: Mechanisms of immune escape or malignant transformation.Seminars in hematology · 2022Review
- Single-cell characterization of leukemic and non-leukemic immune repertoires in CD8Nature communications · 2022Article
- Persistent Large Granular Lymphocyte Clonal Expansions: "The Root of Many Evils"-And of Some Goodness.Cancers · 2022Review
- Isolated anemia in patients with large granular lymphocytic leukemia (LGLL).Blood cancer journal · 2022Article
- Mature T-Cell leukemias: Challenges in Diagnosis.Frontiers in oncology · 2022Review
- Neutropenia and Large Granular Lymphocyte Leukemia: From Pathogenesis to Therapeutic Options.Cells · 2021Review
- Review
- A non-cytotoxic regimen of decitabine to treat refractory T-cell large granular lymphocytic leukemia.Clinical case reports · 2021Article
- Article
Corrections and comments
- Commented on by
Authors and funding
17 authors.
Jibran DurraniDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Hassan AwadaDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Ashwin KishtagariDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Valeria VisconteDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Cassandra KerrDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Vera AdemaDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Yasunobu NagataDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Teodora KuzmanovicDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Sanghee HongDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Bhumika PatelDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Aziz NazhaDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Alan LichtinDepartment of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Sudipto MukherjeeDepartment of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Yogen SaunthararajahDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Hetty CarrawayDepartment of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Mikkael SekeresDepartment of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Jaroslaw P MaciejewskiDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. maciejj@ccf.org.
Funding
TRANSLATIONAL RESEARCH ONCOLOGY TRAINING GRANTK12CA076917 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI GERSON, STANTON L. · 1997 to 2022
$14.2MTherapeutic Implications of Molecular Defects in Bone Marrow FailureR35HL135795 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MACIEJEWSKI, JAROSLAW P. · 2017 to 2023
$5.7MNovel Spliceosomal Defects in Myelodysplastic SyndromesR01HL132071 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MACIEJEWSKI, JAROSLAW P., PADGETT, RICHARD A · 2016 to 2019
$2.4MRNA Helicase Mutations in Myelodysplastic Syndrome: New Therapeutic TargetR01HL123904 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI JANKOWSKY, ECKHARD, MACIEJEWSKI, JAROSLAW P. · 2015 to 2018
$2.1MInvestigations of Consequences of U2AF1 Mutations in MDSR01HL118281 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MACIEJEWSKI, JAROSLAW P., PADGETT, RICHARD A · 2013 to 2017
$1.9MNCI NIH HHS K12 CA076917NHLBI NIH HHS R01 HL118281NHLBI NIH HHS R01 HL123904NHLBI NIH HHS R01 HL132071NHLBI NIH HHS R35 HL135795
Abstract
PubMed holds no abstract for this paper.
Indexed as
AgedAged, 80 and overCell ProliferationFemaleHumansLeukemia, Large Granular LymphocyticMaleMiddle AgedMyelodysplastic SyndromesMyeloid CellsT-Lymphocytes
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.